Document is current
Any future updates will be listed below
-
Authors
Avery, Thomas D. http://orcid.org/0000-0001-6882-5461
Li, Jiahe
Turner, Dion J. L. http://orcid.org/0000-0002-5503-6380
Rasheed, Mohd S. U.
Cherry, Fisher R. http://orcid.org/0009-0001-7646-8422
Stachura, Damian L. http://orcid.org/0000-0002-4895-1062
Rivera-Escalera, Fátima
Ruiz, David M.
Lacagnina, Michael J.
Gaffney, Caitlyn M.
Aguilar, Clarissa
Yu, Jingxian
Wang, Yang
Xie, Huan
Liang, Dong
Shepherd, Andrew J. http://orcid.org/0000-0002-8440-6192
Abell, Andrew D. http://orcid.org/0000-0002-0604-2629
Grace, Peter M. http://orcid.org/0000-0002-8999-1220
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (RF1NS113840, UG3NS127251, UG3NS127251)
Department of Education and Training | Australian Research Council (CE140100003, DP180101581)
Cancer Prevention and Research Institute of Texas (RP180748, RP180748)
U.S. Department of Health & Human Services | National Institutes of Health (U.S. Department of Health & Human Services | National Institutes of Health)
- License Information
-
More Information
Article History
Received: 11 July 2022
Accepted: 2 October 2024
First Online: 4 November 2024
Competing interests
: T.D.A., J.L., D.J.L.T., A.D.A. and P.M.G. are named inventors on patent application WO/2021/179049 and provisional patent application 63/641,731 covering peroxide-activated prodrugs to treat disorders of oxidative stress. T.D.A, A.D.A. and P.M.G. received funding from Biogen. T.D.A., D.J.L.T., A.D.A. and P.M.G. founded and/or hold equity in ImmunoLogic, a start-up company that is developing pathology-activated prodrugs to treat diseases of oxidative stress. The other authors declare no competing interests.
